COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Jcovden (previously COVID-19 Vaccine Janssen)
Active substance
adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)
Therapeutic area (MeSH)
COVID-19 virus infection
Procedure number
EMEA/H/C/005737
Regulatory outcome
Variation
DHPC type
Safety signal
Human ATC code
J07BX03
Dissemination date
19/07/2021

How useful was this page?

Add your rating